Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | G6PD | P11413 | 1/20 | 0.56 |
| ▸ | IDE | P14735 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 9/20 | 0.47 |
| ▸ | CA2 | P00918 | 9/20 | 0.47 |
| ▸ | CA9 | Q16790 | 9/20 | 0.47 |
| ▸ | CA12 | O43570 | 8/20 | 0.47 |
| ▸ | CA5A | P35218 | 8/20 | 0.47 |
| ▸ | CA7 | P43166 | 8/20 | 0.47 |
| ▸ | CA5B | Q9Y2D0 | 8/20 | 0.47 |
| ▸ | CA4 | P22748 | 7/20 | 0.47 |
| ▸ | CA6 | P23280 | 7/20 | 0.47 |
| ▸ | CA14 | Q9ULX7 | 7/20 | 0.47 |
| ▸ | APEX1 | P27695 | 2/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2908276 | 0.88 | G6PD (0.60) | G6PDIDESMN1; SMN2CA1CA2 | |
| SCHEMBL1807656 | 0.85 | CA2 (0.63) | CA1CA2CA9CA12CA5A | |
| SCHEMBL7956783 | 0.84 | G6PD (0.52) | G6PDIDESMN1; SMN2CA1CA2 | |
| SCHEMBL343565 | 0.82 | G6PD (0.55) | G6PDIDESMN1; SMN2CYP2C9CYP2C19 | |
| SCHEMBL4103700 | 0.80 | LMNA (0.53) | G6PDIDESMN1; SMN2CA1CA2 | |
| SCHEMBL31196659 | 0.80 | LMNA (0.53) | G6PDIDESMN1; SMN2CA1CA2 | |
| SCHEMBL898422 | 0.79 | G6PD (0.64) | G6PDIDESMN1; SMN2CA1CA2 | |
| SCHEMBL31705201 | 0.78 | SMN1; SMN2 (0.46) | G6PDIDESMN1; SMN2CA1CA2 | |
| SCHEMBL11009995 | 0.78 | LMNA (0.51) | SMN1; SMN2CA1CA2CA9CA12 | |
| SCHEMBL6932811 | 0.78 | G6PD (0.58) | G6PDIDECA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210380548-A1 | Fused [1,2,4]Thiadiazine Derivatives Which Act as KAT Inhibitors of the MYST Family | CTXT PTY LIMITED (AU) | 2021-12-09 | — | — | US | disclosed |
| US-20210380548-A1 | Fused [1,2,4]Thiadiazine Derivatives Which Act as KAT Inhibitors of the MYST Family | CTXT PTY LIMITED (AU) | 2021-12-09 | — | — | US | disclosed |
| EP-3676266-A1 | FUSED [1,2,4]THIADIAZINE DERIVATIVES WHICH ACT AS KAT INHIBITORS OF THE MYST FAMILY | Ctxt Pty Ltd (AU) | 2020-07-08 | — | — | EP | disclosed |
| WO-2019043139-A1 | FUSED [1,2,4]THIADIAZINE DERIVATIVES WHICH ACT AS KAT INHIBITORS OF THE MYST FAMILY | CTXT PTY LIMITED (AU) | 2019-03-07 | — | — | WO | disclosed |
| WO-2019043139-A1 | FUSED [1,2,4]THIADIAZINE DERIVATIVES WHICH ACT AS KAT INHIBITORS OF THE MYST FAMILY | CTXT PTY LIMITED (AU) | 2019-03-07 | — | — | WO | disclosed |
| US-7268129-B2 | Fluorinated benzothiadiazine compounds | LES LABORATOIRES SERVIER (FR) | 2007-09-11 | — | — | US | disclosed |
| CN-1308317-C | New fluorinated benzothiadiazine compounds, a process for their preparation and pharmaceutical compositions containing them | SERVIER LAB (FR) | 2007-04-04 | — | — | CN | disclosed |
| CN-1680343-A | New fluorinated benzothiadiazine compounds, a process for their preparation and pharmaceutical compositions containing them | SERVIER LAB (FR) | 2005-10-12 | — | — | CN | disclosed |
| US-20050165008-A1 | Fluorinated benzothiadiazine compounds | LES LABORATORIES SERVIER (FR) | 2005-07-28 | — | — | US | disclosed |
| EP-1557412-A1 | Fluorinated benzothiadiazine derivatives and their use as AMPA receptor modulators | Les Laboratoires Servier (FR) | 2005-07-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210380548-A1 | Fused [1,2,4]Thiadiazine Derivatives Which Act as KAT Inhibitors of the MYST Family | KAT5, KAT6A, KAT2A | G6PD 2243/4885IDE 4629/4885SMN1; SMN2 2885/4885 |
| US-20050165008-A1 | Fluorinated benzothiadiazine compounds | GRM1, GRIN1, GRIK5 | G6PD 4189/4885IDE 4741/4885SMN1; SMN2 2970/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.